MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Начало・Списък с акции・Myriad Genetics Inc

Myriad Genetics Inc

Затворен

СекторЗдравеопазване

4.63 -2.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.66

Максимум

4.8100000000000005

Ключови измерители
By Trading Economics
Приходи	20M -7.9M
Продажби	4.1M 210M
Марж на печалбата	-3.765
Служители	2,700
EBITDA	-50M -60M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+40.9% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-11M 408M
Предишно отваряне	6.74
Предишно затваряне	4.63

Настроения в новините

By Acuity

13%

87%

24 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 7.55 Подкрепа & съпротива

Myriad Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.04.2026 г., 23:17 ч. UTC

Печалби

Samsung Forecasts Record First-Quarter Operating Profit

6.04.2026 г., 23:00 ч. UTC

Горещи акции

Stocks to Watch: Health Insurers, Mawson, Owlet

6.04.2026 г., 22:13 ч. UTC

Значими двигатели на пазара

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6.04.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6.04.2026 г., 16:56 ч. UTC

Значими събития в новините

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6.04.2026 г., 14:47 ч. UTC

Значими двигатели на пазара

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6.04.2026 г., 23:58 ч. UTC

Пазарно говорене

Значими събития в новините

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6.04.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6.04.2026 г., 23:15 ч. UTC

Пазарно говорене

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6.04.2026 г., 22:14 ч. UTC

Пазарно говорене

Correction to Live Cattle Futures Article

6.04.2026 г., 20:56 ч. UTC

Пазарно говорене

Mexican Private Consumption Fell in January -- Market Talk

6.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

6.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6.04.2026 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6.04.2026 г., 19:06 ч. UTC

Пазарно говорене

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6.04.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 17:59 ч. UTC

Пазарно говорене

Значими събития в новините

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6.04.2026 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 16:33 ч. UTC

Пазарно говорене

Oil Futures Steady as Market Awaits Trump -- Market Talk

6.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.04.2026 г., 14:59 ч. UTC

Печалби

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Myriad Genetics Inc Прогноза

Ценова цел

By TipRanks

40.9% нагоре

12-месечна прогноза

Среден 6.58 USD 40.9%

Висок 8.5 USD

Нисък 4 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Myriad Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Myriad Genetics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 7.55Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Настроение

By Acuity

24 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.